Initiate Entresto and Aldactone While Weaning Milrinone
You should begin sacubitril/valsartan (Entresto) and spironolactone (Aldactone) now while simultaneously weaning milrinone, rather than waiting until the inotrope is completely discontinued. The goal is to establish guideline-directed medical therapy (GDMT) as early as possible to improve mortality and quality of life, even in patients with advanced heart failure requiring inotropic support 1.
Rationale for Concurrent Initiation
GDMT Should Not Be Delayed
Lack of aldosterone antagonist use is not mandatory before initiating sacubitril/valsartan - there is no evidence requiring spironolactone to be established first, and absence of MRA therapy should not delay ARNI initiation 1.
Both medications can be started during advanced heart failure states - the 2025 European Heart Failure Association guidelines emphasize optimizing GDMT even in patients with low blood pressure or requiring inotropic support 1.
Recent evidence supports combining these agents during hospitalization - a 2025 study demonstrated that initiating sacubitril/valsartan with spironolactone during acute decompensated heart failure stabilization did not significantly increase overall adverse drug reactions (24% vs 20%, p=0.629), though hyperkalemia risk was higher (10% vs 0%, p=0.022) 2.
Specific Implementation Strategy
Starting Sacubitril/Valsartan on Milrinone
Begin with the lowest dose (24/26 mg twice daily) for de novo ARNI initiation or if the patient is ACEI/ARB naive, on low-dose ACEI/ARB, has severe renal impairment (eGFR <30), or is elderly (≥75 years) 1.
Observe a 36-hour washout period if transitioning from an ACEI to avoid angioedema risk; no washout is required when switching from an ARB 1.
Expect 18% intolerance rate in advanced heart failure - predictors of intolerance include lower mean arterial pressure, lower serum chloride, presence of ICD/CRT, moderate or greater mitral regurgitation, and non-use of ACEI/ARB at screening 3.
Starting Spironolactone Concurrently
Initiate spironolactone at 25 mg daily as the target dose for mortality benefit 1.
Monitor potassium and creatinine closely - check labs 1-2 weeks after initiation given the 10% hyperkalemia risk when combined with sacubitril/valsartan 2.
Hold if potassium ≥5.5 mmol/L or creatinine doubles - these are established thresholds for dose reduction or temporary discontinuation 1.
Milrinone Weaning Strategy
Gradual Reduction While Establishing GDMT
Begin weaning milrinone once GDMT is initiated at low doses - as cardiac output potentially improves with neurohormonal blockade, blood pressure may stabilize allowing further medication titration 1.
Monitor for signs of decompensation during wean - watch for increasing dyspnea, fatigue, edema, weight gain (>1.5-2.0 kg over 2 days), which may require doubling diuretic dose or temporarily slowing the wean 1.
Milrinone is primarily renally cleared - dosing concerns exist in acute renal failure or end-stage renal disease, making the transition to GDMT even more important for long-term management 4.
Critical Monitoring Parameters
First 1-2 Weeks
Blood pressure monitoring - asymptomatic hypotension does not require intervention, but symptomatic hypotension (dizziness, confusion) may necessitate reducing diuretics if no congestion is present 1.
Renal function and electrolytes - check within 1-2 weeks after initiation and 1-2 weeks after final dose titration 1.
Daily weights - patients should weigh themselves daily and increase diuretics if weight rises >1.5-2.0 kg over 2 days 1.
Signs of congestion - assess for dyspnea, edema, jugular venous distension 1.
Specific Thresholds for Intervention
Hyperkalemia (K+ ≥5.5 mmol/L) - reduce or hold spironolactone 1, 2.
Symptomatic hypotension with SBP <90 mmHg - this was the most common reason (59%) for sacubitril/valsartan intolerance in advanced heart failure 3.
Creatinine doubling - reduce or hold both medications 1.
Common Pitfalls to Avoid
Do not wait for complete milrinone wean before starting GDMT - this delays mortality-reducing therapy and misses the opportunity to optimize treatment during a monitored setting 1.
Do not stop medications for asymptomatic low blood pressure - only symptomatic hypotension requires intervention 1.
Do not require target-dose spironolactone before starting sacubitril/valsartan - these can be titrated independently 1.
Do not up-titrate both medications simultaneously - increase one drug at a time with 1-2 week intervals and close observation 1.
Up-Titration After Stabilization
Titrate sacubitril/valsartan to target dose (97/103 mg twice daily) over 3-6 weeks using gradual increments 1.
Both condensed (3 weeks) and conservative (6 weeks) titration approaches are similarly tolerated, but gradual titration maximizes target dose attainment 1.
Sometimes blood pressure improves as cardiac output increases - allowing easier medication up-titration over time 1.